AU3681095A - Method and pharmaceutical composition for prevention and treatment of brain damage - Google Patents
Method and pharmaceutical composition for prevention and treatment of brain damageInfo
- Publication number
- AU3681095A AU3681095A AU36810/95A AU3681095A AU3681095A AU 3681095 A AU3681095 A AU 3681095A AU 36810/95 A AU36810/95 A AU 36810/95A AU 3681095 A AU3681095 A AU 3681095A AU 3681095 A AU3681095 A AU 3681095A
- Authority
- AU
- Australia
- Prior art keywords
- prevention
- treatment
- pharmaceutical composition
- brain damage
- brain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Vascular Medicine (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US1994/010752 WO1996009318A1 (en) | 1994-09-22 | 1994-09-22 | Method and pharmaceutical composition for prevention and treatment of brain damage |
WOUS9410752 | 1994-09-22 | ||
PCT/US1995/012057 WO1996009064A1 (en) | 1994-09-22 | 1995-09-21 | Method and pharmaceutical composition for prevention and treatment of brain damage |
Publications (1)
Publication Number | Publication Date |
---|---|
AU3681095A true AU3681095A (en) | 1996-04-09 |
Family
ID=22243017
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU36810/95A Abandoned AU3681095A (en) | 1994-09-22 | 1995-09-21 | Method and pharmaceutical composition for prevention and treatment of brain damage |
Country Status (3)
Country | Link |
---|---|
JP (1) | JPH10505863A (en) |
AU (1) | AU3681095A (en) |
WO (2) | WO1996009318A1 (en) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6017533A (en) * | 1996-04-25 | 2000-01-25 | Shiseido Company, Ltd. | Peptides having specific affinity to pituitary adenylate cyclase activating polypeptide type 1 receptors |
US6165755A (en) * | 1997-01-23 | 2000-12-26 | University Of Victoria Innovation And Development Corporation | Chicken neuropeptide gene useful for improved poultry production |
ES2335827T3 (en) * | 1998-07-20 | 2010-04-05 | Ipsen Pharma | PACAP PEPTIDAL ANALOGS. |
US6242563B1 (en) | 1998-07-20 | 2001-06-05 | Societe De Conseils De Recherches Et D'applications Scientifiques, Sas | Peptide analogues |
EP1423509A2 (en) | 2001-08-30 | 2004-06-02 | Stem Cell Therapeutics Inc. | Differentiation of neural stem cells and therapeutic use thereof |
JP4906231B2 (en) | 2001-09-14 | 2012-03-28 | ステム セル セラピューティクス インコーポレイテッド | Prolactin-induced increase in neural stem cell number and its therapeutic use |
EP1507551A2 (en) * | 2002-05-03 | 2005-02-23 | Neuronova AB | The functional role and potential therapeutic use of pacap, vip and maxadilan in relation to adult neural stem or progenitor cells |
AU2003250705A1 (en) * | 2002-07-31 | 2004-02-16 | Stem Cell Therapeutics Inc. | Method of enhancing neural stem cell proliferation, differentiation, and survival using pituitary adenylate cyclase activating polypeptide (pacap) |
EP1740202B1 (en) | 2004-02-13 | 2012-05-09 | Stem Cell Therapeutics Corp. | Use of luteinizing hormone (lh) and chorionic gonadotropin (hcg) for proliferation of neural stem cells and neurogenesis |
WO2005102375A1 (en) * | 2004-04-23 | 2005-11-03 | Senju Pharmaceutical Co., Ltd. | Corneal neuritogenesis promoter containing pacap and its derivative |
EP1778268B1 (en) | 2004-07-21 | 2016-05-04 | Tulane University Health Sciences Center | Treatment of renal dysfunction and multiple myeloma using pacap compounds |
CA2664629A1 (en) | 2005-09-27 | 2007-04-05 | Christopher Gregg | Oligodendrocyte precursor cell proliferation regulated by prolactin |
EP2004211A4 (en) | 2006-03-17 | 2010-07-07 | Stem Cell Therapeutics Corp | Dosing regimes for lh or hcg and epo for treatment of neurological disorders |
WO2009046876A2 (en) * | 2007-09-11 | 2009-04-16 | Mondobiotech Laboratories Ag | Use of a peptide as a therapeutic agent |
WO2009043519A2 (en) * | 2007-09-11 | 2009-04-09 | Mondobiotech Laboratories Ag | Use of a peptide as a therapeutic agent |
EP2197467A2 (en) * | 2007-09-11 | 2010-06-23 | Mondobiotech Laboratories AG | Use of adrenomedullin as a therapeutic agent for the treatment of excessive angiogenesis |
AU2010313122A1 (en) * | 2009-11-02 | 2012-05-24 | The Administrators Of The Tulane Educational Fund | Analogs of pitutary adenylate cyclase-activating polypeptide (PACAP) and methods for their use |
ITMI20110583A1 (en) | 2011-04-08 | 2012-10-09 | Hmfra Hungary Ltd Liability Company | OPHTHALMIC PREPARATIONS BASED ON PACAP (PITUITARY ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE) FOR THE PURPOSE OF RESTORING THE NORMAL VISUAL FUNCTION IN THE GLAUCOMA EARLY |
JPWO2019098254A1 (en) * | 2017-11-14 | 2020-12-03 | 千寿製薬株式会社 | PACAP Stabilizing Peptide |
WO2020230869A1 (en) * | 2019-05-14 | 2020-11-19 | 千寿製薬株式会社 | Composition for preventing or treating neurotrophic keratitis which contains pacap peptide or stabilized pacap peptide |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5128242A (en) * | 1989-06-19 | 1992-07-07 | The Administrators Of The Tulane Educational Fund | Hypothalamic polypeptides with adenylate cyclase stimulating activity |
US5198542A (en) * | 1989-06-20 | 1993-03-30 | Takeda Chemical Industries, Inc. | Dna encoding a pitvitary adenylate cyclase activating protein and use thereof |
EP0768090A3 (en) * | 1990-07-18 | 1997-06-18 | Takeda Chemical Industries Ltd | Polypeptides having c-AMP producing activity for the prevention of neuronal cell death |
US5344644A (en) * | 1991-08-01 | 1994-09-06 | Takeda Chemical Industries, Ltd. | Water-soluble composition for sustained-release |
JPH06228002A (en) * | 1993-01-29 | 1994-08-16 | Takeda Chem Ind Ltd | Secretgranin ii production promoter containing pacap |
-
1994
- 1994-09-22 WO PCT/US1994/010752 patent/WO1996009318A1/en active Search and Examination
- 1994-09-22 JP JP8510838A patent/JPH10505863A/en not_active Ceased
-
1995
- 1995-09-21 AU AU36810/95A patent/AU3681095A/en not_active Abandoned
- 1995-09-21 WO PCT/US1995/012057 patent/WO1996009064A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
JPH10505863A (en) | 1998-06-09 |
WO1996009318A1 (en) | 1996-03-28 |
WO1996009064A1 (en) | 1996-03-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU3681095A (en) | Method and pharmaceutical composition for prevention and treatment of brain damage | |
AU2277595A (en) | Device and method for treatment of skin | |
AU2103195A (en) | Device and method for treatment of dentition | |
AU4995693A (en) | Apparatus and method for the treatment of blood | |
AU1436595A (en) | Method of treatment of traumatic brain injury | |
AU1976695A (en) | Method and apparatus for treatment of atrial fibrillation | |
AU2187992A (en) | Composition and method for disease treatment | |
AU5439996A (en) | Compositions and methods for treating pain | |
AU2296995A (en) | Composition and method for treatment of cmv infection | |
AUPO727097A0 (en) | Method of treatment of hepatoma and pharmaceutical compositions for use therein | |
EP1014972A4 (en) | Method of treatment and pharmaceutical composion | |
AU2180097A (en) | Composition for prevention and treatment of periodontal diseases | |
PL309600A1 (en) | Pharmaceutical compositions for preventing and treating neoplastic diseases and method of obtaining them | |
AUPO359396A0 (en) | A method of treatment and pharmaceutical compositions useful for same | |
AU3768795A (en) | Method and compositions for hair treatment | |
HUP9501807A2 (en) | Method for treatment of asbestcement products | |
AU8369998A (en) | Medicinal product and method for treatment and prevention of cognitive disorders | |
ZA9510108B (en) | Composition and method for prevention and treatment of HIV-1 infection | |
AU3607597A (en) | Pharmaceutical composition for prophylaxis and/or treatment of apoptosis-related diseases | |
AU4104093A (en) | Method and compositions for treatment of pyonecrotic processes | |
AU2750297A (en) | Methods for prevention and/or treatment of neutropenia | |
AU2992295A (en) | Therapeutic method and compounds of use therein | |
AU4521497A (en) | Method and apparatus for the treatment of organic matter | |
AU6979594A (en) | Compositions and methods for treatment and prevention of retinal dysfunctions | |
AUPM836794A0 (en) | Improved method and composition for the treatment of ulcers |